NEW YORK, June 3 - Indian bioinformatics company Strand Genomics said on Friday it is set to announce a number of "overseas" biopharma collaborations.
The first of these partnerships, which will likely be announced next Monday, will be with Clinigene, a subsidiary of Biocon India, and focus on diabetes, according to Strand.
A second deal, which should be announced in July or August, will be with a US-based biopharma. Each of these partnerships will be given access to Strand's technology to help identify disease-specific biomarkers and SNPs.
Bangalore-based Strand also plans to grow its bioinformatics team to 100 from 65 by the end of the year, according to Sreeni Devidas, vice president for business development and strategy.
"Several top recruits" will be joining Strand from US firms in the next two months, Devidas said in an e-mail message.
Click here for more information.